Overview

Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101)

Status:
Active, not recruiting
Trial end date:
2021-10-29
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of avelumab when combined with either crizotinib or PF-06463922.
Phase:
Phase 2
Details
Lead Sponsor:
Pfizer
Treatments:
Avelumab
Crizotinib